INTRODUCTION
< Asthma is one of the most common long term medical condition, with around 300 million 1 people affected world wide < Asthma is an important contributor to the burden of illness and people with asthma experience poor life satisfaction and require a range of health services to manage their 2 condition < Dependence on medication, regular hospital visit, and inability to fully integrate with peers 3 are aspects that could negatively influence the quality of life (QoL) 
RESULTS

OBJECTIVES
What is the impact of severe asthma in symptoms and well-being of adults and children?
< What is the overall impact in HRQoL?
< How is this impact distributed by the different dimensions of HRQoL: Physical Symptomscoughing, wheezing, shortness of breath; Physical functioning -e.g. walking upstairs, exercise, sleep disruption; Disability -e.g. restriction in ability to perform normal activities, limited ability for activities of daily living; Psychological -mental and emotional health, behavior; Social -daily role, work, personal relationships
METHODOLOGY
A targeted literature search was conducted of the relevant published evidence from the following databases:
Retrieved citations and full texts were screened according to the following inclusion criteria:
< Disease: Severe asthma (both allergic and non-allergic asthma)
< Patient population: Both adults (≥18 years) and children (6-17 years)
< Study designs: Both randomized controlled trials (RCTs) and observational studies < Outcomes: Baseline QoL data either measured on generic scale or disease-specific scale Four studies compared AQLQ scores based on different severities of asthma . Of these, three studies were conducted in adults while one study assessed children < Data also suggested that patients with severe asthma have rapid deterioration in overall health status as compared to patients with mild-moderate asthma < AQLQ was the most frequently used scale among the included studies, assessed in 13 studies followed by St George's Respiratory Questionnaire (SGRQ) in six studies < Higher proportion of adult patients were receiving inhaled corticosteroids (ICS) + Long-acting beta-agonists (LABA) (35.4% -100.0%) followed by ICS (74.4% -84.0%), anti-leukotrienes (4.6% -86.3%), Rapid-acting beta agonists (RABA) (42.4% -77.0%), and Short-acting beta-agonists (SABA) (24.1% -45.1%)
< Most common pharmacological treatments prescribed in children were ICS (100%) followed by LABA (87.0% -96.0%) and anti-leukotrienes (71.0% -100.0%) 
